Objectives: In Spain it is necessary to conduct additional studies to determine place in therapy and cost-effectiveness of a drug. The main objective of this study is to identify all drug assessments and health technology assessment reports of the drugs for gastroenteropancreatic (GEP) neuroendocrine tumors (NET) at a national, regional and hospital level and to summarize the efficacy in terms of outcome measures, adverse events, economic impact and final recommendations.
Methods: A search was made on the GENESIS website for drug evaluation reports regarding GEP NET, including gastrointestinal and bronchopulmonary, to identify the drug assessments at a regional and hospital level. 8 reviews at regional and hospital level were considered. Two clinical guidelines have been reviewed to determine the current management and available treatments.
Results: Surgery is the main treatment for NETs in different phases of their evolution. If there is recurrence there are other possible treatments as chemotherapy, somatostatin analogues and new biological agents, also called \"targeted treatments\", that currently have a palliative and symptom control role, since they rarely achieve the elimination of the disease themselves.
Conclusions: Everolimus and sunitinib are new drugs available for the treatment of GEP NET patients reported to have promising effects in advanced diseases. However, the reports are limited and thus new clinical studies on the impact of these drugs on clinical outcome, prognosis, financial burden and feasibility are necessary to support further recommendations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deproteinized Bovine Bone Mineral With Collagen for Anterior Maxillary Ridge Augmentation: A Retrospective Cohort Study.
Clin Implant Dent Relat Res
February 2025
Department of Implantology, The Affiliated Hospital of Stomatology, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, China.
Objectives: This study aimed to assess the effects of deproteinized bovine bone mineral with collagen (DBBMC) combined with deproteinized bovine bone mineral (DBBM) on facial alveolar bone augmentation in the anterior maxillary region.
Materials And Methods: Patients receiving dental implant placement with simultaneous lateral bone augmentation using DBBM (control group) or DBBMC combined with DBBM (test group) were included in the study. The radiographic assessment of facial alveolar bone, such as facial horizontal bone thickness (FHBT), facial vertical bone level (FVBL), and square of facial bone (SFB), was taken by cone beam computed tomography (CBCT).
Time to neonatal mortality and its predictors among preterm neonates admitted to the neonatal intensive care unit in northern Ethiopia, 2023/2024: a retrospective cohort study.
Arch Public Health
January 2025
Department of Maternity and Neonatal Nursing, School of Nursing, College of Health Sciences, Comprehensive Specialized Hospital, Aksum University, Aksum, Tigray, Ethiopia.
Background: A preterm neonate is defined by the World Health Organization as a child delivered before 37 weeks of gestation. In low- and middle-income countries, including Ethiopia, preterm-related complications are serious health problems due to increases in the mortality and morbidity of newborns and children under 5 years of age. The aim of this study was to assess the time to neonatal mortality and its predictors among preterm neonates admitted to the neonatal intensive care unit in northern Ethiopia, 2023/2024.
View Article and Find Full Text PDFTargeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.
J Exp Clin Cancer Res
January 2025
Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a poor prognosis. The critical role of epigenetic alterations such as changes in DNA methylation, histones modifications, and chromatin remodeling, in pancreatic tumors progression is becoming increasingly recognized. Moreover, in PDAC these aberrant epigenetic mechanisms can also limit therapy efficacy.
View Article and Find Full Text PDFThe interaction of tPA with NMDAR1 drives neuroinflammation and neurodegeneration in α-synuclein-mediated neurotoxicity.
J Neuroinflammation
January 2025
Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.
The thrombolytic protease tissue plasminogen activator (tPA) is expressed in the CNS, where it regulates diverse functions including neuronal plasticity, neuroinflammation, and blood-brain-barrier integrity. However, its role in different brain regions such as the substantia nigra (SN) is largely unexplored. In this study, we characterize tPA expression, activity, and localization in the SN using a combination of retrograde tracing and β-galactosidase tPA reporter mice.
View Article and Find Full Text PDFPoikiloderma with neutropenia: a case report.
J Med Case Rep
January 2025
Department of Pediatrics, University Children Hospital, Damascus University, Damascus, Syria.
Background: Poikiloderma with neutropenia is a rare genetic disorder primarily characterized by the presence of poikiloderma and congenital chronic neutropenia. Mutations in the C16orf57 gene, which encodes the USB1 protein, are implicated as the underlying cause of poikiloderma with neutropenia.
Case Presentation: Our patient, an 11-year-old Syrian male child who presented with poikiloderma, palmoplantar keratoderma, pachyonychia, recurrent infections, and neutropenia, is considered to be the first documented case in Syria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!